Published in J Immunol on April 01, 2006
B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73
Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol (2013) 2.49
HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol (2009) 2.23
Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med (2007) 2.20
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog (2007) 1.90
HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS (2009) 1.67
Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. J Virol (2008) 1.54
Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol (2011) 1.53
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2013) 1.51
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
Scaffold functions of 14-3-3 adaptors in B cell immunoglobulin class switch DNA recombination. PLoS One (2013) 1.46
Innate immune recognition and activation during HIV infection. Retrovirology (2010) 1.45
Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS (2011) 1.42
Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol (2008) 1.41
HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol (2009) 1.39
Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection. PLoS Pathog (2014) 1.39
Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J Immunol (2008) 1.35
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood (2006) 1.35
Tissue-specific B-cell dysfunction and generalized memory B-cell loss during acute SIV infection. PLoS One (2009) 1.30
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses (2011) 1.30
DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog (2006) 1.25
HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res (2010) 1.24
Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Curr Opin HIV AIDS (2007) 1.24
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol (2013) 1.23
Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses. Crit Rev Immunol (2010) 1.22
Innate control of B cell responses. Trends Immunol (2011) 1.21
Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J Virol (2011) 1.17
Intestinal bacteria condition dendritic cells to promote IgA production. PLoS One (2008) 1.13
B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med (2010) 1.11
CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One (2010) 1.09
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09
Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma. J Proteome Res (2010) 1.07
Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. J Virol (2010) 1.07
B lymphocyte activation by coinfection prevents immune control of friend virus infection. J Immunol (2008) 1.06
Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood (2008) 1.05
Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. J Virol (2007) 1.05
Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. J Clin Invest (2014) 1.04
The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression. Nat Immunol (2013) 1.04
Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. PLoS One (2009) 1.03
CD27(-) B-cells produce class switched and somatically hyper-mutated antibodies during chronic HIV-1 infection. PLoS One (2009) 1.02
Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells. J Virol (2007) 1.01
Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol (2014) 0.96
Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection. Immunology (2009) 0.96
Alterations of the B-cell response by HIV-1 replication. Curr HIV/AIDS Rep (2011) 0.95
HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells. Scientifica (Cairo) (2013) 0.93
Intrusive HIV-1-infected cells. Nat Immunol (2009) 0.93
HIV-associated memory B cell perturbations. Vaccine (2015) 0.92
Opportunities to exploit non-neutralizing HIV-specific antibody activity. Curr HIV Res (2013) 0.91
Role of IL-21 and IL-21 receptor on B cells in HIV infection. Crit Rev Immunol (2012) 0.90
Marginal zone B-cells, a gatekeeper of innate immunity. Front Immunol (2011) 0.90
Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. Hum Vaccin Immunother (2012) 0.89
Mucosal immunity to HIV: a review of recent literature. Curr Opin HIV AIDS (2008) 0.89
B cell lymphoma in HIV transgenic mice. Retrovirology (2013) 0.88
Immune responses to HIV in the female reproductive tract, immunologic parallels with the gastrointestinal tract, and research implications. Am J Reprod Immunol (2011) 0.87
Rotavirus differentially infects and polyclonally stimulates human B cells depending on their differentiation state and tissue of origin. J Virol (2010) 0.86
Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment. Clin Dev Immunol (2012) 0.86
HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells. J Immunol (2012) 0.86
Dendritic cell status modulates the outcome of HIV-related B cell disease progression. PLoS Pathog (2011) 0.85
HIV-1 transmission by dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) is regulated by determinants in the carbohydrate recognition domain that are absent in liver/lymph node-SIGN (L-SIGN). J Biol Chem (2009) 0.85
Innate immune evasion strategies by human immunodeficiency virus type 1. ISRN AIDS (2013) 0.85
Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proc Natl Acad Sci U S A (2015) 0.85
BAFF mediates splenic B cell response and antibody production in experimental Chagas disease. PLoS Negl Trop Dis (2010) 0.84
Influence of dendritic cells on B-cell responses during HIV infection. Clin Dev Immunol (2012) 0.84
Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front Microbiol (2013) 0.82
Genetic immunization converts the trypanosoma cruzi B-Cell mitogen proline racemase to an effective immunogen. Infect Immun (2009) 0.82
Immune surveillance and lymphoid malignancy in immunocompromised host. Am J Blood Res (2013) 0.82
Generation of hypoallergenic neoglycoconjugates for dendritic cell targeted vaccination: a novel tool for specific immunotherapy. J Control Release (2012) 0.81
Modulation of human immune responses by bovine interleukin-10. PLoS One (2011) 0.80
The impact of inflammation and immune activation on B cell differentiation during HIV-1 infection. Front Immunol (2012) 0.80
Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice. Proc Natl Acad Sci U S A (2016) 0.80
Premature B-cell senescence as a consequence of chronic immune activation. Hum Vaccin Immunother (2014) 0.80
HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape. Pathog Dis (2015) 0.79
Decreased mutation frequencies among immunoglobulin G variable region genes during viremic HIV-1 infection. PLoS One (2014) 0.78
An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells. PLoS One (2013) 0.78
T cell independent secondary antibody responses to the envelope protein of simian immunodeficiency virus. Retrovirology (2012) 0.78
Direct phenotypical and functional dysregulation of primary human B cells by human immunodeficiency virus (HIV) type 1 in vitro. PLoS One (2012) 0.78
Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens. J Immunol (2014) 0.77
How do viruses trick B cells into becoming lymphomas? Curr Opin Hematol (2014) 0.76
Control of Viremia Enables Acquisition of Resting Memory B Cells with Age and Normalization of Activated B Cell Phenotypes in HIV-Infected Children. J Immunol (2015) 0.76
Coexistence of intestinal Kaposi sarcoma and plasmablastic lymphoma in an HIV/AIDS patient: case report and review of the literature. J Gastrointest Oncol (2016) 0.75
Type I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection. Front Immunol (2016) 0.75
Inflammatory Markers and Immune Response to Pneumococcal Vaccination in HIV-Positive and -Negative Adults. PLoS One (2016) 0.75
Blood B Lymphocyte Stimulator (BLyS)/BAFF levels may reflect natural immunity to HIV in highly exposed uninfected Beninese Commercial Sex Workers. Sci Rep (2016) 0.75
Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy? Curr Opin Virol (2016) 0.75
Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. Front Immunol (2016) 0.75
Subversion of the B-cell compartment during parasitic, bacterial, and viral infections. BMC Immunol (2015) 0.75
Preservation of peripheral T follicular helper cell function in HIV controllers. J Virol (2017) 0.75
Lower Baseline Germinal Center Activity and Preserved Th1 Immunity Are Associated With Hepatitis B Vaccine Response in Treated HIV Infection. Pathog Immun (2017) 0.75
Viral infections associated with oral cancers and diseases in the context of HIV: a workshop report. Oral Dis (2016) 0.75
Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma. For Immunopathol Dis Therap (2015) 0.75
The Role of BAFF System Molecules in Host Response to Pathogens. Clin Microbiol Rev (2017) 0.75
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A (2005) 12.96
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol (2002) 6.85
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity (2007) 4.87
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
AIDS vaccine models: challenging challenge viruses. Nat Med (2002) 3.92
Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science (2013) 3.74
B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol (2011) 3.66
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Online submission makes authors do all the work. Nature (2005) 3.21
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
The genetic landscape of mutations in Burkitt lymphoma. Nat Genet (2012) 3.03
V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 3.00
Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol (2007) 2.96
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A (2013) 2.96
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood (2008) 2.85
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med (2008) 2.81
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell (2010) 2.73
Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol (2006) 2.71
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med (2004) 2.58
The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol (2010) 2.55
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A (2011) 2.39
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med (2009) 2.26
HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol (2009) 2.23
Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemia. Am J Clin Pathol (2011) 2.18
Whither or wither microbicides? Science (2008) 2.17
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood (2011) 2.15
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology (2005) 2.13
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A (2013) 2.10
CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol (2004) 2.08
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 2.05
Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol (2004) 2.01
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis (2010) 2.00
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res (2004) 2.00
Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol (2009) 1.97
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 1.97
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology (2006) 1.97
Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood (2003) 1.93
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2002) 1.93
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med (2005) 1.92
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog (2007) 1.90
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood (2002) 1.89
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A (2009) 1.87
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood (2006) 1.86
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol (2010) 1.86
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol (2009) 1.84
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology (2004) 1.72